UniSuper Management Pty Ltd Acquires 1,724 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

UniSuper Management Pty Ltd increased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 20.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,033 shares of the medical research company's stock after acquiring an additional 1,724 shares during the quarter. UniSuper Management Pty Ltd's holdings in Charles River Laboratories International were worth $1,852,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Cerity Partners LLC raised its position in Charles River Laboratories International by 65.9% during the third quarter. Cerity Partners LLC now owns 4,891 shares of the medical research company's stock valued at $963,000 after acquiring an additional 1,943 shares in the last quarter. Glenmede Trust Co. NA raised its position in shares of Charles River Laboratories International by 9.5% during the third quarter. Glenmede Trust Co. NA now owns 1,210 shares of the medical research company's stock valued at $238,000 after buying an additional 105 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Charles River Laboratories International in the 3rd quarter valued at approximately $2,915,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Charles River Laboratories International by 4.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,812 shares of the medical research company's stock worth $1,933,000 after purchasing an additional 423 shares during the period. Finally, Public Sector Pension Investment Board boosted its position in shares of Charles River Laboratories International by 15.1% during the 3rd quarter. Public Sector Pension Investment Board now owns 2,282 shares of the medical research company's stock valued at $449,000 after acquiring an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Remove Ads

Charles River Laboratories International Trading Down 2.9 %

Shares of CRL stock traded down $4.03 during mid-day trading on Friday, hitting $136.95. The company's stock had a trading volume of 1,666,195 shares, compared to its average volume of 770,520. The company's fifty day simple moving average is $162.49 and its 200-day simple moving average is $180.95. Charles River Laboratories International, Inc. has a 52 week low of $133.05 and a 52 week high of $258.56. The company has a market cap of $7.00 billion, a PE ratio of 912.99, a P/E/G ratio of 4.54 and a beta of 1.45. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm's revenue was down 1.1% compared to the same quarter last year. During the same period in the previous year, the company posted $2.46 EPS. As a group, equities research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO James C. Foster acquired 6,075 shares of the company's stock in a transaction that occurred on Thursday, February 20th. The shares were acquired at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the purchase, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have issued reports on CRL. Redburn Atlantic upgraded Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective for the company in a research note on Monday, March 3rd. Citigroup raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and lifted their target price for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. Robert W. Baird reduced their price objective on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a research note on Thursday, February 20th. Morgan Stanley decreased their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a report on Wednesday, February 5th. Finally, Barclays lowered their price target on Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating for the company in a report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $189.77.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).